Cargando…

Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements

This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.

Detalles Bibliográficos
Autores principales:	Spetz, Joanne, Hailer, Laurie, Gay, Caryl, Tierney, Matthew, Schmidt, Laura, Phoenix, Bethany, Chapman, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099425/ https://www.ncbi.nlm.nih.gov/pubmed/35552728 http://dx.doi.org/10.1001/jamanetworkopen.2022.5996

Ejemplares similares

Analysis of US County Characteristics and Clinicians With Waivers to Prescribe Buprenorphine After Changes in Federal Education Requirements
por: Nguyen, Thuy, et al.
Publicado: (2022)

Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US
por: Duncan, Alexandra, et al.
Publicado: (2020)

Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
por: Jones, Christopher M., et al.
Publicado: (2023)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver
por: Lanham, Holly J., et al.
Publicado: (2022)

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
por: Silwal, Anita, et al.
Publicado: (2023)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes
por: Hirchak, Katherine A., et al.
Publicado: (2022)

Buprenorphine Waiver Attitudes Among Primary Care Providers
por: Lai, Benjamin, et al.
Publicado: (2022)

Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic
por: Jones, Christopher M., et al.
Publicado: (2021)

Trends in Buprenorphine Prescribing for Opioid Use Disorder by Psychiatrists in the US From 2003 to 2021
por: Creedon, Timothy B., et al.
Publicado: (2023)

Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder
por: Solmeyer, Anna R., et al.
Publicado: (2022)

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

Self-reported Use of Prescribed Buprenorphine Among US Adults With Nonmedical Use of Prescription Opioids Motivated by Pain
por: Buonora, Michele J., et al.
Publicado: (2022)

A Descriptive Study on Opioid Misuse Prevalence and Office-Based Buprenorphine Access in Ohio Prior to the Removal of the Drug Addiction Treatment Act of 2000 Waiver
por: McKnight, Erin R, et al.
Publicado: (2023)

Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
por: Weiner, Scott G., et al.
Publicado: (2023)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Comparison of Opioids Prescribed by Advanced Practice Clinicians vs Surgeons After Surgical Procedures in the US
por: Priest, Caitlin R., et al.
Publicado: (2023)

A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers
por: Stoller, Kenneth B
Publicado: (2015)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Improve Access to Care for Opioid Use Disorder: A Call to Eliminate the X-Waiver Requirement Now
por: D’Onofrio, Gail, et al.
Publicado: (2021)

Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
por: Aldabergenov, D, et al.
Publicado: (2022)

Training Clinicians to Support Aging in Place in a Medicaid Home and Community-Based Waiver Program
por: Spoelstra, Sandra, et al.
Publicado: (2020)

Prescribing Buprenorphine for Opioid Use Disorders in the ED: A Review of Best Practices, Barriers, and Future Directions
por: Cao, Scott S, et al.
Publicado: (2020)

US Support for a WTO Waiver of COVID-19 Intellectual Property
por: Contreras, Jorge L.
Publicado: (2021)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Peripartum and Postpartum Analgesia and Pain in Women Prescribed Buprenorphine for Opioid Use Disorder Who Deliver by Cesarean Section
por: O’Connor, Alane B, et al.
Publicado: (2022)

A Call to Action: Integration of Buprenorphine Prescribing Into the Care of Persons With Human Immunodeficiency Virus and Opioid Use Disorder
por: Fujita, A Wendy, et al.
Publicado: (2022)

Get waivered remote: Nationwide, remote DEA-x waiver course in response to COVID-19
por: Martin, Alister, et al.
Publicado: (2021)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

A qualitative examination of the current management of opioid use disorder and barriers to prescribing buprenorphine in a Canadian emergency department
por: Wiercigroch, David, et al.
Publicado: (2021)

The pressing shortage of buprenorphine prescribers and the pending role of telemedicine
por: Molfenter, Todd
Publicado: (2015)

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
por: Neale, Joanne, et al.
Publicado: (2019)

Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
por: Dunlop, Adrian J., et al.
Publicado: (2021)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries
por: Wheelock, Kevin M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i323m191qtbju05p6njob65d9n